NCT02552576View on ClinicalTrials.gov

Study of Voncento® in Subjects With Von Willebrand Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 5, 2015

Primary Completion Date

February 15, 2018

Study Completion Date

February 15, 2018

Conditions
Von Willebrand Disease
Interventions
BIOLOGICAL

Voncento

Human coagulation VWF / coagulation factor VIII (FVIII) complex concentrate

Trial Locations (12)

Unknown

Study Site, Vienna

Study Site, Duisburg

Study Site, Frankfurt

Study Site, Athens

Study Site, Krakow

Study Site, Rzeszów

Study Site, Wroclaw

Study Site 14, London

Study Site 40, London

Study Site 42, London

Study Site 47, London

Study Site 8, London

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY